The market starts on another down day as the Dog Days of August persist in whittling away the positive backdrop of the …
BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. Valoctocogene roxaparvovec is a treatment for severe hemophilia. “We …
BioMarin Pharmaceutical Inc. BMRN reported earnings of 3 cents per share in the first quarter of 2017 (including stock-based compensation expense), significantly better than the year-ago loss of 36 cents and the Zacks Consensus …